000 Cancer Drug: How Much Is a Life Worth?

It costs $93,000 and adds four months’ survival, normally, for males with incurable prostate tumors. Bob Svensson is honest about why he got it: insurance paid. ‘I would not spend that cash,’ because the benefit doesn’t seem worthwhile, says Svensson, 80, a former corporate finance officer from Bedford, Mass. ’60 Minutes’: The Cost of Dying His supplemental Medicare plan is paying as the government decides whether fundamental Medicare will cover Provenge and for whom. The tab for taxpayers could possibly be huge – prostate may be the most common tumor in American men. Continue reading 000 Cancer Drug: How Much Is a Life Worth?

Yes weve all seen the Bollywood movies in exuberant design.

Getting mehndi performed on your own hands and foot is great before your best friend’s wedding as well. Obtain your hen party to decorate from head to toe and experience Bollywood glamorous. Bollywood Nights out Do you like dance to cheesy Bollywood tunes? Well why not make your hen night time different from the ordinary ordinary down the nightclub and mind for a Bollywood night out? It’s a little bit like venturing out to a 70s night or an 80s night you enter the spirit of this period of music. Continue reading Yes weve all seen the Bollywood movies in exuberant design.

Access receives 1st MuGard prescriptions and reimbursement Access Pharmaceuticals.

Access receives 1st MuGard prescriptions and reimbursement Access Pharmaceuticals, Inc Click to read more . Through its consultants and specialty distribution partner, Gain access to’ outreach to payor systems for MuGard prescription reimbursement is usually ongoing. ‘Receiving the first MuGard prescriptions marks a major milestone inside our Company’s work in getting MuGard to the UNITED STATES cancer supportive care marketplace,’ said Frank Jacobucci, VP of Advertising and Sales for Access Pharmaceuticals, Inc.’. Continue reading Access receives 1st MuGard prescriptions and reimbursement Access Pharmaceuticals.

AVEO Pharmaceuticals reports net loss of $14.

Net reduction guidance is based upon an expected weighted typical share count of 24.8 million. Expenses related to the TIVO-1 trial in 2010 2010 are anticipated to range between $27 million and $30 million, based upon current estimates for patient accrual rates. The business expects to have a year-end balance of a minimum of $50 million in money, cash equivalents and marketable securities. Recent Accomplishments far Thus, this year, the ongoing company provides made important progress toward achievement of its corporate goals in 2010 2010. Key accomplishments consist of: Related StoriesCrucial modify in one DNA base predisposes kids to aggressive form of cancerMeat-rich diet may increase kidney malignancy riskNew findings show association between colorectal cancer and melanoma drug treatmentInitiated Individual Enrollment in Phase 3 Clinical Trial: AVEO initiated patient enrollment in TIVO-1, a global Phase 3 medical trial of tivozanib in individuals with advanced RCC.S. Continue reading AVEO Pharmaceuticals reports net loss of $14.